Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA places IND on hold for PRAX-114 in major depressive disorder

Nov. 11, 2020

Small-molecule compound targets amyloid beta

Nov. 11, 2020

Antigen agnostic tolerizing therapy in MS

Nov. 11, 2020

FDA issues complete response letter for SPN-812 for ADHD

Nov. 10, 2020

A promising multitarget antipsychotic among piperidine-amide substituted derivatives

Nov. 10, 2020

FDA approves Sesquient to treat status epilepticus in adult and pediatric patients

Nov. 9, 2020

Synerkine Pharma discloses new IL-13-comprising fusion proteins

Nov. 9, 2020

FDA approves Brilinta to reduce the risk of stroke in acute ischemic stroke or high-risk TIA

Nov. 9, 2020

Hinova Pharmaceuticals describes PROTAC androgen receptor degraders

Nov. 6, 2020

Phase IIb/III study opens in U.S. with mesdopetam for troublesome dyskinesias in Parkinson's

Nov. 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...